

***Fiscal Year 2015 Amyotrophic Lateral Sclerosis Research Program  
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Therapeutic Development Award</b></p> <p><b>Go to:</b>  <a href="#">Program Announcement</a>  <a href="#">General Application Instructions</a></p> <p><b>Grants.gov Funding Opportunity Number:</b>  <a href="#">W81XWH-15-ALSRP-TDA</a></p>	<p>Independent investigators at all academic levels</p>	<ul style="list-style-type: none"> <li>• <b>Pre-application is required; application submission is by invitation only.</b></li> <li>• Supports post-discovery, preclinical development of therapeutics for ALS</li> <li>• Types of efforts that will be supported include:               <ul style="list-style-type: none"> <li>○ Post-discovery validation;</li> <li>○ Demonstration of target selectivity and mechanism of action, optimization of potency and pharmacology, studies of formulation, stability and production methods based on Good Manufacturing Practices, ADME studies;</li> <li>○ Development of pharmacological agents up to IND submission;</li> <li>○ Development of biomarkers of action on specific molecular targets or of clinical progress to support development of therapeutics.</li> </ul> </li> <li>• Preliminary data relevant to the phase of preclinical development are required.</li> <li>• Clinical trials are not allowed under this mechanism.</li> <li>• <b>New for FY15:</b> Does not support screening, or development of screens or models.</li> </ul>	<ul style="list-style-type: none"> <li>• Maximum funding of \$1,000,000 for direct costs (plus indirect costs)</li> <li>• <b>New for FY15:</b> Maximum period of performance is 2 years.</li> </ul>	<p><b>Pre-Application:</b> May 11, 2015 5:00 p.m. Eastern Time (ET)</p> <p><b>Application:</b> August 20, 2015 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Therapeutic Idea Award</b></p> <p><b>Go to:</b>  <a href="#">Program Announcement</a>  <a href="#">General Application Instructions</a></p> <p><b>Grants.gov Funding Opportunity Number:</b>  <a href="#">W81XWH-15-ALSRP-TIA</a></p>	<p>Independent investigators at all academic levels</p>	<ul style="list-style-type: none"> <li>• <b>Pre-application is required; application submission is by invitation only.</b></li> <li>• Supports hypothesis-driven drug and drug target discovery efforts focused on ALS therapeutics.</li> <li>• Studies should focus on discovery of novel drug targets and discovery of drugs based on novel targets or modes of action.</li> <li>• Innovation and impact are primary criteria</li> <li>• Preliminary data are not required.</li> <li>• <b>New for FY15:</b> Supports development, validation and use of novel of high-throughput screens and model systems based on novel targets or innovative drug systems.</li> </ul>	<ul style="list-style-type: none"> <li>• The maximum period of performance is <b>2</b> years.</li> <li>• The maximum allowable funding for the entire period of performance is <b>\$500,000</b> in direct costs.</li> <li>• Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.</li> </ul>	<p><b>Pre-Application:</b>  May 11, 2015  5:00 p.m. ET</p> <p><b>Application:</b>  August 20, 2015  11:59 p.m. ET</p>